A Systematic Review and Meta-analysis of Intravenous Palonosetron in the Prevention of Chemotherapy-induced Nausea and Vomiting in Adults

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2011 Feb 2

PMID 21282670

Citations 22

Authors

Zhou Likun

Jing Xiang

Ba Yi

Duan Xin

Zheng Liu Tao

Affiliations

Soon will be listed here.

Abstract

Objectives: We performed a systematic review and meta-analysis to compare treatment effectiveness and adverse effects in cancer patients receiving chemotherapy with palonosetron to prevent chemotherapy-induced nausea and vomiting (CINV).

Methods: We identified randomized controlled clinical trials (RCT) comparing palonosetron with first-generation 5-HT3RA in the prevention of CINV in cancer patients. Meta-analyses were performed on homogeneous studies. Fixed or random-effects models were used to combine data.

Results: Eight eligible trials were identified, reporting outcomes on 3,592 patients. Meta-analyses showed statistically significant differences in favor of palonosetron compared with first-generation 5-HT3RA in prevention of acute CINV (p = .0003), delayed CINV (p < .00001), and overall phase of CINV (p < .00001). Subgroup analyses showed statistically significant differences in favor of both 0.25 mg and 0.75 mg of palonosetron in prevention of all phases of CINV. There were no statistically significant differences between 0.25 and 0.75 mg of palonosetron. Compared with the first-generation 5-HT3RA, 0.75 mg of palonosetron showed a statistically significant difference in the occurrence of constipation (p = .04).

Interpretation: The use of palonosetron should be considered an integral part of adjuvant therapy for prevention of the acute, delayed, and overall phases of CINV. The 0.25 mg intravenous palonosetron dose is as effective as the 0.75 mg intravenous palonosetron dose. However, 0.75 mg intravenous palonosetron causes constipation more frequently than the first-generation 5-HT3RA.

Citing Articles

Safety and Feasibility of Outpatient Zolbetuximab Administration in Community Cancer Care: A Mixed-methods Analysis.

Yakuwa E, Shoji Y, Oizumi T, Kobayashi Y, Motoishi T, Katagiri T In Vivo. 2025; 39(2):951-960.

PMID: 40010971 PMC: 11884467. DOI: 10.21873/invivo.13900.

Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society....

Nakashima K, Yokomizo A, Murakami M, Okita K, Wada M, Iino K Int J Clin Oncol. 2024; 29(12):1785-1794.

PMID: 39417943 DOI: 10.1007/s10147-024-02643-8.

Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis.

Yamaguchi A, Saito Y, Takekuma Y, Sugawara M Support Care Cancer. 2023; 32(1):58.

PMID: 38145979 DOI: 10.1007/s00520-023-08283-4.

Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.

Inui N, Toi Y, Yoneshima Y, Morise M, Hata A, Kubota K Adv Ther. 2023; 40(11):4928-4944.

PMID: 37715851 PMC: 10567891. DOI: 10.1007/s12325-023-02648-1.

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.

Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K J Clin Oncol. 2021; 40(2):180-188.

PMID: 34793245 PMC: 8718175. DOI: 10.1200/JCO.21.01315.

References

Hasler W . Serotonin receptor physiology: relation to emesis. Dig Dis Sci. 1999; 44(8 Suppl):108S-113S. View

Eisenberg P, MacKintosh F, Ritch P, Cornett P, Macciocchi A . Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004; 15(2):330-7. DOI: 10.1093/annonc/mdh047. View

Kris M, Hesketh P, Somerfield M, Feyer P, Clark-Snow R, Koeller J . American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24(18):2932-47. DOI: 10.1200/JCO.2006.06.9591. View

Herrington J, Jaskiewicz A, Song J . Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008; 112(9):2080-7. DOI: 10.1002/cncr.23364. View

Sepulveda-Vildosola A, Betanzos-Cabrera Y, Lastiri G, Rivera-Marquez H, Villasis-Keever M, Del Angel V . Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res. 2008; 39(6):601-6. DOI: 10.1016/j.arcmed.2008.04.007. View

Rojas C, Stathis M, Thomas A, Massuda E, Massuda E, Alt J . Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008; 107(2):469-78. DOI: 10.1213/ane.0b013e318172fa74. View

Kuo B, Camilleri M, Burton D, Viramontes B, McKinzie S, Thomforde G . Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther. 2002; 16(2):225-33. DOI: 10.1046/j.1365-2036.2002.01144.x. View

Aapro M, Macciocchi A, Gridelli C . Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol. 2005; 3(5):369-74. View

Kleisbauer J, Garcia-Giron C, Antimi M, Azevedo M, Balmes H, Contu A . Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs. 1998; 9(5):387-92. DOI: 10.1097/00001813-199806000-00003. View

10.

Coates A, Abraham S, Kaye S, Sowerbutts T, Frewin C, Fox R . On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983; 19(2):203-8. DOI: 10.1016/0277-5379(83)90418-2. View

11.

Nielsen O, Lund P, Langholz E . Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion. 1990; 46(2):89-96. DOI: 10.1159/000200337. View

12.

Herrstedt J . Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2007; 5(1):32-43. DOI: 10.1038/ncponc1021. View

13.

Navari R . Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol. 2006; 2(5):591-602. DOI: 10.2217/14796694.2.5.591. View

14.

Lindley C, Hirsch J, ONeill C, Transau M, GILBERT C, Osterhaus J . Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992; 1(5):331-40. DOI: 10.1007/BF00434947. View

15.

Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C . Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic.... Ann Oncol. 2010; 21(5):1083-8. DOI: 10.1093/annonc/mdp584. View

16.

Gore S, Gilmore I, Haigh C, Brownless S, Stockdale H, Morris A . Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther. 1990; 4(2):139-44. DOI: 10.1111/j.1365-2036.1990.tb00458.x. View

17.

Fauser A, Pizzocaro G, Schueller J, Khayat D, Wilkinson P . A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer. 2000; 8(1):49-54. DOI: 10.1007/s005209900090. View

18.

Lorusso V, Spedicato A, Petrucelli L, Saracino V, Giampaglia M, Perrone T . Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer. 2009; 17(12):1469-73. DOI: 10.1007/s00520-009-0611-9. View

19.

. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med. 1995; 332(1):1-5. DOI: 10.1056/NEJM199501053320101. View

20.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H . Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10(2):115-24. DOI: 10.1016/S1470-2045(08)70313-9. View